<DOC>
	<DOCNO>NCT02138812</DOCNO>
	<brief_summary>Determine safety , tolerability , maximum tolerate dose ( MTD ) , recommend Phase II dose ( RP2D ) BAY1161909 combination paclitaxel subject advanced malignancy .</brief_summary>
	<brief_title>Phase I Dose Escalation Oral BAY1161909 Combination With Intravenous Paclitaxel</brief_title>
	<detailed_description>BAY 1161909 potent highly selective inhibitor monopolar spindle 1 ( Mps1 ) kinase activity . Human Mps1 serine threonine kinase function core component spindle assembly checkpoint ( SAC ) , key surveillance mechanism monitor attachment spindle microtubule kinetochore chromosome pro-metaphase halt transition anaphase chromosome bi-oriented , fully attach , correctly tense metaphase plate . Mps1 express mitosis phase cell cycle proliferate cell . Overexpression Mps1 observe several cancer cell line tumor type include lung breast cancer . Established anti-mitotic drug vinca alkaloid , taxanes , epothilones activate SAC either destabilize stabilize spindle microtubule result mitotic arrest . Prolonged arrest mitosis force cell either mitotic exit without cytokinesis mitotic catastrophe lead cell death . In contrast , Mps1 inhibitor inactivate SAC accelerate progression cell mitosis eventually result severe chromosomal missegregation , mitotic catastrophe , cell death . Consequently , Mps1 inhibition lead failure cell arrest mitosis response anti-mitotic drug . Thus , combination microtubule-interfering agent Mps1 inhibition strongly increase chromosomal segregation error cell death therefore , constitute efficient strategy selectively eliminate tumor cell . This study attempt answer follow question : - What side effect BAY 1161909 give different dose level schedule paclitaxel ? - What dose level schedule BAY 1161909 test future clinical research study ? - How much BAY 1161909 paclitaxel blood specific time administration ? - Does treatment BAY 1161909 paclitaxel show effect tumor growth ? - Are specific biomarkers might able explain patient respond treatment others .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male female subject age =/ &gt; 18 year Subjects advance , histologically cytologically confirm advanced malignancy ( solid tumor ) , refractory standard therapy , standard therapy available , subject actively refuse standard treatment / , judgment investigator , experimental treatment clinically ethically acceptable . For expansion cohort : woman histologically cytologically confirm TNBC ( triple negative breast cancer ) Subjects must evaluable measurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 12 week Adequate bone marrow , liver , renal function Known hypersensitivity study drug excipients preparation agent give association study Evidence peripheral neuropathy Grade &gt; 2 History cardiac disease : congestive heart failure New York Heart Association ( NYHA ) class &gt; II , unstable angina ( anginal symptom rest ) , newonset angina ( within past 3 month study entry ) , myocardial infarction within past 3 month study entry , cardiac arrhythmia require antiarrhythmic therapy ( beta blocker , calcium channel blocker , digoxin permit ) Prior treatment 3 line cytostatic therapy metastatic disease unless specifically agree investigator sponsor . Subjects history prior Grade =/ &gt; 3 toxicity associate taxane treatment exclude . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg , despite optimal medical management Moderate severe hepatic impairment , i.e . ChildPugh class B C History human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>MPS-1 inhibitor</keyword>
	<keyword>Taxanes</keyword>
</DOC>